rosiglitazone has been researched along with MPTP Neurotoxicity Syndrome in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carta, AR; Lecca, D; Mulas, G; Pisanu, A; Simbula, G; Spiga, S; Wardas, J | 1 |
Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N | 1 |
2 other study(ies) available for rosiglitazone and MPTP Neurotoxicity Syndrome
Article | Year |
---|---|
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Topics: Animals; Cell Count; Cell Polarity; Cytokines; Disease Models, Animal; Gene Expression Regulation; Mice; Microglia; MPTP Poisoning; Nerve Degeneration; Neuroprotective Agents; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tyrosine 3-Monooxygenase | 2014 |
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liquid; Chronic Disease; Disease Models, Animal; Dopamine; Drug Interactions; Dynorphins; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Globus Pallidus; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; PPAR gamma; Psychomotor Performance; RNA, Messenger; Rosiglitazone; Smell; Tandem Mass Spectrometry; Thiazolidinediones; Tyrosine 3-Monooxygenase | 2009 |